Silver nanoplate compositions and methods

Abstract
Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoplates, such as silver nanoplates or silver platelet nanoparticles, and to nanoparticles, solutions and substrates prepared by said methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates. The process can also include increasing the concentration of silver nanoplates within the solution, and thus increasing the solution optical density.
Description
BACKGROUND

1. Field of the Invention


Various embodiments of the invention relate to methods for preparing high optical density solutions of silver platelet nanoparticles (e.g., nanoplates) and to nanoparticles, solutions and substrates prepared by said methods.


2. Description of the Related Art


Nanoparticles, including nanospheres, nanorods, nanowires, nanocubes, nanoplates, as well as other shapes can be synthesized from a range of materials. Nanoparticles made from metals including gold and silver have unique optical properties which can be tuned to interact with light throughout the electromagnetic spectrum due to the localized surface plasmon resonance supported by these nanomaterials. Technologies that take advantage of the unique optical properties of silver nanoparticles, (e.g., such as silver nanoplates), include, but are not limited to, diagnostic, photonic, medical, and obscurant technologies. A subset of these technologies including photothermal tumor ablation, hair removal, acne treatment, wound healing, and antimicrobial applications among others, may use solutions of nanoparticles with high optical densities. Silver platelet nanoparticles, which are also known as silver nanoplates or silver nanoprisms, are of particular interest for technologies that utilize nanoparticle optical properties due to their tunable spectral peaks and extremely high optical efficiencies. While methods to fabricate silver platelet nanoparticles via photoconversion (Jin et al. 2001; Jin et al. 2003), pH-controlled photoconversion (Xue 2007), thermal growth (Hao et al. 2004; Hao 2002; He 2008; Metraux 2005), templated growth (Hao et al. 2004; Hao 2002), and seed mediated growth (Aherne 2008; Chen; Carroll 2003; Chen; Carroll 2002, 2004; Chen et al. 2002; He 2008; Le Guevel 2009; Xiong et al. 2007) have been developed, these methods generate relatively dilute solutions with correspondingly low visible and near-infrared optical densities, (e.g., such as optical densities of less than 10 cm−1, such as 1-9 cm−1, 5-10 cm−1).


SUMMARY

For many silver nanoplate applications, a more concentrated solution of the silver nanoplates is of utility and can be particularly advantageous. In some instances, when the as-fabricated solutions of silver nanoplates are concentrated to yield a higher particle density under previously developed methods, the shape of the particle can undergo a change resulting in a shift in the solution optical properties. In many cases, these changes result in an undesirable degradation of their optical properties. Accordingly, several embodiments of the present invention provide methods for preparing high optical density solutions of silver nanoplates from dilute silver nanoplate solutions that substantially or fully preserve the optical properties of as-fabricated silver nanoplates when the particle concentration is increased. The high optical density solutions of silver nanoplates can be exposed to substrates to generate nanoplate composites with high loading levels.


Various embodiments of the invention provide a method for preparing high optical density solutions of silver platelet nanoparticles, as well as the nanoparticles and solutions prepared by those methods. In one embodiment, the process comprises the replacement of one or more original components (e.g., chemical or biological agents) bound, or otherwise coupled to, the nanoparticle surface with a stabilizing agent. The stabilizing agent can be a biological or chemical agent that stabilizes the nanoplates before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates. In one embodiment, the process also comprises a method of increasing the concentration of silver nanoplates within the solution, and thus increasing the solution optical density. In several embodiments, the stability (e.g., the characteristics of the nanoparticles in the solution, such as shape, size, optical properties, peak response, plasmonic properties, etc.) of the high optical density solution is unaffected or substantially unaffected during the process.


In one embodiment, a high optical density solution comprises silver nanoplates that have been stabilized with stabilizing agents (e.g., surface bound molecules chemical agents, and/or biological agents). In various embodiments, a solution of silver platelet nanoparticles (e.g., silver nanoplates) have been surface functionalized with chemical or biological agents that are physisorbed to the surface, molecularly bound to the surface through specific interactions, or encapsulate each nanoplate on its surface.


In one embodiment, a high optical density solution of silver nanoplates is associated with a substrate. In one embodiment, a portion of the nanoplates in solution bind to the substrate to create a nanoplate-substrate composite. The high optical density solutions of silver nanoplates can be exposed to substrates to generate nanoplate composites where a substantial portion of the surface area of a substrate is coated with nanoplates. In some embodiments the substrate comprises fibers, cloth, mesh, bandages, socks, wraps, other articles of clothing, sponges, high porosity substrates, particles with edge lengths greater than 1 micron, beads, hair, skin, paper, absorbent polymers, foam, wood, cork, slides, roughened surfaces, biocompatible substrates, filters, and/or medical implants.


In several embodiments, a process for increasing the optical density of a solution of stable, silver nanoplates comprises the following: (i) providing a solution comprising silver nanoplates having a plate shape, a first extinction spectra, and a first peak optical density between 0.1-10 cm−1; (ii) adding a concentration stabilizing chemical agent to the solution of silver nanoplates; and (iii) increasing the concentration of silver nanoplates using tangential flow filtration, thereby increasing the optical density of the solution to a second peak optical density greater than 10 cm−1, wherein the silver nanoplates comprise the plate shape and the first extinction spectra at the optical density greater than 10 cm−1.


In various embodiments, the stabilizing agent comprises or consists essentially of at least one of the group consisting of polyvinyl pyrollidone, polyvinyl alcohol, polyethylene glycol, and dextran. In various embodiments, the stabilizing agent comprises or consists essentially of at least one of the group consisting of polysulphonates, ethylene oxides, phenols, and carbohydrates. In one embodiment, the concentration stabilizing chemical agent is a water soluble polymer. In one embodiment, the concentration stabilizing chemical agent is a metal or metalloid oxide. In one embodiment, the stabilizing chemical agent is a silicon dioxide shell. In various embodiment, the silicon dioxide shell ranges in thickness from 1 nm to 100 nm. In one embodiment, the stabilizing chemical agent is a titanium dioxide shell. In various embodiments, a combination of stabilizing agents are used.


In various embodiments, the process further comprises adding any of the group selected from an acid, a base, and a buffering agent to the solution. In one embodiment, the silver nanoplates have an aspect ratio of between 1.5 and 25. In one embodiment, the nanoplate has an edge length between 10 nm and 250 nm. In some embodiments, the solution of silver nanoplates is formed using a seed mediated growth method. In one embodiment, the concentration of silver nanoplates is washed with between 1 and 5 wash volumes after increasing the concentration using tangential flow filtration. In one embodiment, the solution of silver nanoplates is incubated with a substrate.


In various embodiments, a process for generating a solution of silver nanoplates with high optical density comprises the following: (i) providing a solution of silver nanoplates with a first peak optical density between 0.1-10 cm−1, (ii) adding a concentration stabilizing chemical agent to the solution of silver nanoplates; (iii) adding a buffer to the solution of silver nanoplates; and (iv) increasing the concentration of the silver nanoplates to increase the optical density of the solution greater than 10 cm−1.


In one embodiment, the concentration stabilizing chemical agent comprises a derivative of a vinyl polymer. In one embodiment, the polymer is polyvinyl alcohol (PVA). In one embodiment, the polymer is polyvinyl pyrrolidone (PVP). In one embodiment, the process further comprises adding one of the group consisting of sodium bicarbonate and sodium borate to the solution.


In several embodiments, a process for generating a solution of silver nanoplates with extremely high optical density comprises the following: (i) adding a concentration stabilizing chemical agent to a solution of silver nanoplates or precursor reagents and (ii) increasing the concentration of silver nanoplates to increase the optical density of the solution.


In various embodiments, the silver nanoplates have an aspect ratio of between 1.5 and 25 (e.g., 1.5-10, 25-50); and/or the nanoplate has an edge length between about 10 nm and 250 nm (e.g., 50-250, 65-100 nm); and/or the nanoplate is triangular in cross section; and/or the nanoplate is circular in cross section. In one embodiment, the perimeter of the nanoplate cross section has between 4 and 8 edges (e.g., 4, 5, 6, 7, 8). In various embodiments, the solution of silver nanoplates is formed using one or more of a photoconversion method, a pH-controlled photoconversion method, a thermal growth method, a seed mediated growth method, and/or a solution comprising a shape stabilizing agent or agents and a silver source. In various embodiments, chemical or biological agents, and/or electromagnetic radiation, and/or heat, or a combination thereof are used to reduce the silver source. In one embodiment, the solution of silver nanoplates is formed from some combination of a reducing agent, a shape stabilizing agent, a light source, a heat source, and a silver source.


In one embodiment, an acid, base, or buffering agent is added to change the solution pH. In various embodiments, the concentration stabilizing chemical agent is added prior to, during, and/or after the formation of the silver nanoplates. In one embodiment, the concentration stabilizing chemical agent acts as a shape stabilizing agent. In one embodiment, the concentration stabilizing chemical agent acts as a reducing agent. In one embodiment, the concentration stabilizing chemical agent acts as an agent to change the solution pH.


In one embodiment, the concentration stabilizing chemical agent is a water soluble polymer. In various embodiments, the polymer is any one or more of a derivative of polysulfonate, sodium polystyrene sulfonate, a derivative of a vinyl polymer, and a polyvinyl alcohol (PVA). In various embodiments, the PVA has a molecular weight of less than about 80,000 Dalton (e.g., 1,000-50,000, 25,000-75,000 Dalton), between about 80,000 Dalton and 120,000 Dalton (e.g., 85,000-95,000, 100,000-110,000 Dalton), and/or more than about 120,000 Dalton (e.g., 150,000-300,000 Dalton). In one embodiment, the polymer is polyvinylpyrrolidone (PVP). In various embodiments, the PVP has a molecular weight of less than about 20,000 Dalton (e.g., 2,000-12,000 Dalton), more than about 20,000 Dalton (e.g., 35,000-400,000 Dalton), between about 20,000 Dalton and 60,000 Dalton (e.g., 40,000-55,000 Dalton), and/or more than about 60,000 Dalton (e.g., 70-100,000, 90-150,000 Dalton). In one embodiment, the polymer is an ethylene oxide derivative.


In one embodiment, the polymer is a polyethylene glycol (PEG). In various embodiments, the PEG has a molecular weight of less than about 5,000 Dalton (e.g., 200-3,000, 1,000-4,500 Dalton), between about 5,000 Dalton and 10,000 Dalton (e.g., 7,000-8,000, 6,000-7,500 Dalton), and/or more than about 10,000 Dalton (e.g., 12,000-35,000, 18,000-45,000 Dalton). In one embodiment, the PEG contains a single functional group. In one embodiment, the PEG contains more than one functional group (e.g., two, three, or more functional groups). In one embodiment, the functional group or groups comprise any of an amine, thiol, acrylate, alkyne, maleimide, silane, azide, hydroxyl, lipid, disulfide, fluorescent molecule, and/or biotin. In one embodiment, the functional group or groups can be any one or more of an amine, thiol, acrylate, alkyne, maleimide, silane, azide, hydroxyl, lipid, disulfide, fluorescent molecule, and/or biotin. In one embodiment, the concentration stabilizing agent is a carbohydrate derivative. In various embodiments, the polymer is a monosaccharide, a disaccharide, an oligosaccharide, a polysaccharide, and/or dextran. In various embodiments, the dextran has a molecular weight that is less than about 2,000 Dalton (e.g., 200-1,400, 1,000-1,900 Dalton), between about 2,000 Dalton and 5,000 Dalton (e.g., 3,000-3,500, 2,000-4,000 Dalton), and/or more than about 5,000 Dalton (e.g., 6,000-8,000, 7,000-13,000 Dalton).


In various embodiments, the concentration stabilizing chemical agent is any one or more of a phenol, a monomeric phenol, a dimeric phenol, a trimeric phenol, a polyphenol, a tannic acid, is gum Arabic, a biological molecule, a protein, a bovine serum albumin, streptavidin, biotin, a peptide, an oligonucleotide, a naturally occurring oligonucleotide, a synthetic oligonucleotide, a metal or metalloid oxide, and/or a silicon dioxide shell. In one embodiment, a silicon dioxide shell has ranges in thickness from about less than 1 nm to about 100 nm (e.g., 10-70, 30-90, 40-60 nm). In one embodiment, a combination of stabilizing agents are used. In various embodiments, the solvent can be one or more of water, an alcohol, ethanol, isopropyl alcohol, t-butanol, a mixture of a water and an alcohol.


In one embodiment, the concentration of silver nanoplates is increased using tangential flow filtration. In one embodiment, the tangential flow filtration is performed using a tangential flow filter membrane. In one embodiment, the tangential flow membrane is made from a cellulose ester or mix of cellulose esters. In various embodiments, the tangential flow membrane is made from one or more of polyetheresulfone and/or polysulfone. In various embodiments, the tangential flow membrane has a molecular weight cut off of less than about 10 kD (e.g., 1-5, 8 kD), of between about 10 kD and 500 kD (e.g., 50-250, 300-400 kD), of more than about 500 kD (e.g., 750, 1000, 5000 kD or more), of less than about 0.05 μm, of between about 0.05 μm and 0.5 μm (e.g., 0.01, 0.03 μm), and/or of more than about 0.5 μm (e.g., 1.0, 2, 5, 10, 100 μm).


In various embodiments, the silver nanoplate solution is concentrated to produce a solution with an optical density of greater than about 10 cm−1 (e.g., 15-45 cm−1, 30-150 cm−1, or more), greater than about 50 cm−1 (e.g., 80-150 cm−1, 60-120 cm−1, 100 cm−1 or more), greater than about 75 cm−1 (e.g., 80-110 cm−1, 200-400 cm−1, 1000 cm−1 or more), greater than about 100 cm−1 (e.g., 150-350 cm−1, 200-400 cm−1 or more), and/or greater than about 500 cm−1(e.g., 600-1500 cm−1, 1000 cm−1 or more).


In one embodiment, the solvent of the concentrated solution is exchanged using tangential flow filtration. In one embodiment, the concentrated solution is processed to remove residual chemicals using tangential flow filtration.


In various embodiments, a solution of nanoparticles comprising silver nanoparticles is coated with a polymer with an optical density greater than 100 cm−1(e.g., 160-550 cm−1, 900-1100 cm−1, 100 cm−1, 1000 cm−1 or more).


In one embodiment, the solution of silver nanoplates is incubated with a substrate (e.g., fibers, cloth, mesh, bandages, socks, wraps, other articles of clothing, sponges, high porosity substrates, particles with edge lengths greater than 1 micron, beads, hair, skin, paper, absorbent polymers, foam, wood, cork, slides, roughened surfaces, biocompatible substrates, filters, and/or medical implants). In one embodiment, the substrate is removed from the solution of silver nanoplates and dried.





BRIEF DESCRIPTION OF THE DRAWINGS

Further objects, features and advantages of the invention will become apparent from the following detailed description taken in conjunction with the accompanying figures showing illustrative embodiments of the invention, in which the following is a description of the drawings. The drawings are examples, and should not be used to limit the embodiments. Moreover, recitation of embodiments having stated features is not intended to exclude other embodiments having additional features or other embodiments incorporating different combinations of the stated features. Further, features in one embodiment (such as in one figure) may be combined with descriptions (and figures) of other embodiments.



FIG. 1 illustrates the optical spectrum of a silver nanoplate solution as fabricated using a photoconversion method according to one embodiment of the present invention. In one embodiment, a silver nanoplate solution is fabricated using a photoconversion method identified as [DSS1099, alternative spectrum ARS1134]—as fabricated, these silver nanoplates have an optical density of less than 1 cm−1.



FIG. 2 illustrates a transmission electron micrograph of silver nanoplates fabricated using a photoconversion method according to one embodiment of the present invention. Scale bar is 50 nm.



FIG. 3 illustrates one embodiment of plates concentrated in the absence of a concentration stabilizing agent with normalized (bottom) and unnormalized (top) extinction spectra of as-fabricated silver nanoplates before and after tangential flow filtration concentration. After concentration the plates have a significantly changed peak shape as demonstrated by the normalized plot, and a spectral peak at 400 nm that demonstrates that a large number of silver nanoplates have turned into silver nanospheres. In one embodiment, plates are concentrated with the identification [MGM1201 and 1195E].



FIG. 4 illustrates one embodiment of plates concentrated in the presence of a concentration stabilizing agent with normalized (bottom) and unnormalized (top) extinction spectra of as-fabricated silver nanoplates before and after tangential flow filtration concentration using a concentration stabilizing agent. After being concentrated the plates retain their spectral peak shape with no increase in the spectral peak at 400 nm. In one embodiment, plates are concentrated with the identification [MGM1282 and 1279A].



FIG. 5 illustrates extinction spectra of high optical density nanoplate solutions processed using the methods described in various embodiments of the invention.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Several embodiments of the present invention comprise processes for making solutions of plasmonic nanoparticle including silver nanoplates that are suitable for performing treatment of a target body region (e.g., such as for tumor ablation, hair removal, acne treatment, wound healing, and antimicrobial applications). Optical Density (O.D.) is the logarithmic ratio of the radiation incident on a material to the radiation transmitted through the material (O.D.=−log10(I1/I0) where I1 is the intensity of transmitted light and I0 is the intensity of the incident light). For solutions, the optical density is a function of the path length through the liquid sample is expressed in units of cm−1. In some instances, optical density is expressed without the unit cm−1—such as in instances in which a standard path length of 1 cm is used.


Silver Nanoplate Physical Description


In one embodiment, silver nanoplates are characterized by lengths along the three principle axes wherein: the axial length of two of the principle axes is at least two times greater than the axial length of the shortest principle axis and the shortest principal axial length is less than about 500 nm.


The ratio of the average of the two longer principle axes to the shorter principle axes is referred to as the aspect ratio. In one embodiment the average aspect ratio of the silver plates is greater than 1.5, 2, 3, 4, 5, 7, 10, 20, 30, or 50, or any range therein (e.g., greater than 8, 9, 11, 12, 13, 14, 15, 25, 35, 40, 45). In various embodiments the average aspect ratio of the silver plates is between 1.5 and 25, 2 and 25, 1.5 and 50, 2 and 50, 3 and 25, or 3 and 50 (e.g., 5 and 20, 10 and 15, 5 and 40, 5 and 30, 5 and 20, 10 and 50, 20 and 50, 30 and 50, 40 and 50, 10 and 20, 20 and 30, 30 and 40, 40 and 50, and any values between 1.5 and 50, inclusive).


In one embodiment the nanoplate has edge lengths less than 500 nm, 250 nm, 200 nm, 150 nm, 100 nm, 80 nm, 60 nm or 50 nm (e.g., 400 nm, 300 nm, 225 nm, 175 nm, 125 nm, 90 nm, 70 nm, 55 nm, and any values between 500 and 50 nm, inclusive). In one embodiment the nanoplate has edge lengths greater than 5 nm, 10 nm, 20 nm, 30 nm, 50 nm or 100 nm, or any value therein or more (e.g., 15, 25, 40, 60, 70 75, 80, 90, 5-100, 20-80, 30-50, 45-95 nm, and/or 30 nm to 100 nm, 20 nm to 150 nm, 10 nm to 200 nm, 10 nm to 300 nm). In one embodiment the nanoplate has a thickness (third principle axis) that is less than 500 nm, 300 nm, 200 nm, 100 nm, 80 nm, 60 nm, 50 nm, 40 nm, 30 nm, 20 nm, or 10 nm, or any value therein (e.g., 400 nm, 250 nm, 150 nm, 75 nm, 5 nm to 20 nm, 5 nm to 30 nm, 10 nm to 30 nm, 10 nm to 50 nm, 10 nm to 100 nm).


Silver nanoplates have a variety of different cross sectional shapes including circular, triangular, or shapes that have any number of discrete edges. In one embodiment the nanoplates have less than 20, 15, 10, 8, 6, 5, or 4 edges (e.g., 18, 12, 11, 9, 2, 1). In one embodiment the nanoplates have more than 2, 3, 4, or 5 edges (e.g., 6, 7, 10, 15, 20 or more). In some embodiments the silver nanoplates have sharp corners and in other embodiments the corners are rounded. In some embodiments of silver nanoplates, there are a variety of different cross sectional shapes within the same sample. In other embodiments of silver nanoplate solutions greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the number of particles in solution are silver nanoplates with the other particles having different shapes including but not limited to spherical, cubic, and irregular. In one embodiment the nanoplates have one or two flat sides. In another embodiment the nanoplates are pyramidal.


Silver Nanoplate Fabrication


The silver nanoplates utilized in various embodiments of this invention may be fabricated using photoconversion (Jin et al. 2001; Jin et al. 2003), pH controlled photoconversion (Xue 2007), thermal growth (Hao et al. 2004; Hao 2002; He 2008; Metraux 2005), templated growth (Hao et al. 2004; Hao 2002), seed mediated growth (Aherne 2008; Chen; Carroll 2003; Chen; Carroll 2002, 2004; Chen et al. 2002; He 2008; Le Guevel 2009; Xiong et al. 2007), or alternative methods. Alternative methods include methods in which the silver nanoplates are formed from a solution comprising a shape stabilizing agent or agents and a silver source, and in which chemical agents, biological agents, electromagnetic radiation, or heat are used to reduce the silver source.



FIG. 1 illustrates the optical spectrum of a silver nanoplate solution as fabricated using a photoconversion method according to one embodiment of the present invention. In one embodiment, a silver nanoplate solution is fabricated using a photoconversion method identified as [DSS1099, alternative spectrum ARS1134]—as fabricated, these silver nanoplates have an optical density of less than 1 cm−1.



FIG. 2 illustrates a transmission electron micrograph of silver nanoplates fabricated using a photoconversion method according to one embodiment of the present invention. In FIG. 2, the scale bar is 50 nm.



FIG. 3 illustrates one embodiment of plates concentrated in the absence of a concentration stabilizing agent with normalized (bottom) and unnormalized (top) optical extinction spectra of as-fabricated silver nanoplates before and after tangential flow filtration concentration. After concentration the plates have a significantly changed peak shape as demonstrated by the normalized plot, and a spectral peak at 400 nm that demonstrates that a large number of silver nanoplates have turned into silver nanospheres. In one embodiment, plates are concentrated with the identification [MGM1201 and 1195E].



FIG. 4 illustrates one embodiment of plates concentrated in the presence of a concentration stabilizing agent with normalized (bottom) and unnormalized (top) optical extinction spectra of as-fabricated silver nanoplates before and after tangential flow filtration concentration using a concentration stabilizing agent. After being concentrated the plates retain their spectral peak shape with no increase in the spectral peak at 400 nm. In one embodiment, plates are concentrated with the identification [MGM1282 and 1279A].



FIG. 5 illustrates optical extinction spectra of high optical density nanoplate solutions processed using the methods described in various embodiments of the invention.


Silver Nanoplate Coating


In one embodiment, silver nanoplates have molecules that are adsorbed or otherwise bound to the particle surface. The molecules on the surface are the reactants or reactant by-products of the synthesis. One object of one embodiment of this invention is to partially or fully exchange the molecules that are bound to the surface of the silver nanoplates with other molecules that more fully protect the particles from changing shape during concentration. Another object of one embodiment of the invention is to use a stabilizing agent during fabrication that generates plate shapes and also stabilizes the nanoplates during subsequent concentration.


In various embodiments, stabilizing agent variants that may be utilized include chemical or biological agents that are physisorbed to the surface, molecularly bound to the surface through specific interactions (e.g. thiol or amine), or encapsulate the surface (i.e. a metal oxide or metalloid oxide shell). In various embodiments, specific chemical agents of interest include polymers such as polysulphonates, vinyl polymers, carbohydrates, ethylene oxides, phenols, and carbohydrates. In various embodiments, specific examples of these polymers include poly(sodium) styrene sulfonate, polyvinyl alcohol, polyvinyl pyrrolidone, tannic acid, dextran, and polyethylene glycol (PEG) including PEG molecules which contain one or more chemical groups (e.g. amine, thiol, acrylate, alkyne, maleimide, silane, azide, hydroxyl, lipid, disulfide, fluorescent molecule, or biomolecule moieties). In various embodiments, specific biomolecules of interest include proteins, peptides, and oligonucleotides, including biotin, bovine serum albumin, streptavidin, neutravidin, wheat germ agglutinin, naturally occurring and synthetic oligonucleotides and peptides, including synthetic oligonucleotides which have one or more chemical functionalities (e.g. amine, thiol, dithiol, acrylic phosphoramidite, azide, digoxigenin, alkynes, or biomolecule moieties). Specific encapsulating chemical agents of interest include metal oxide shells such as SiO2 and TiO2. Stabilizing agents may be added prior to the formation of silver nanoplates, during the formation of silver nanoplates, or after the formation of silver nanoplates. An additional chemical agent of interest is gum arabic.


Carrier Solutions


In one embodiment of this invention the silver nanoplates are fabricated in aqueous solutions. In other embodiments the silver nanoplates are fabricated in other solutions that can include ethanol, isopropanol, or organic solvents such as heptane, toluene, or butanol.


In one embodiment an acid, base or buffering agent (e.g., a buffer) is added to change the solution pH either before, during, or after the addition of a stabilant. In various embodiments, the nanoplates are suspended in a sodium bicarbonate buffer or a sodium borate buffer.


Surface Stabilization


In various embodiments, stabilizing agents can be solid or liquid formulations that are added to the silver plate solution. The stabilizing agents have an affinity for the surface of the silver nanoplates and will associate with the plate surface. In some embodiments, the bound molecules on the silver nanoplates will be displaced by the added stabilizing agents. In some embodiments the stabilants are added to the as-fabricated silver nanoplate solution. In other embodiments, the solution of nanoplates is washed, or the residual reactants are otherwise removed. In other embodiments, the suspending solution is exchanged with a different suspending media which includes ethanol, isopropanol, or other polar or non-polar liquids before the stabilizing agents are added.


Once the stabilizing agent is added, the mixture of the stabilant and the silver nanoplates can undergo a number of different processes including heating, boiling, boiling under reflux, rotoevaporation, vacuum, stirring, stirring with magnetic stir bars, stirring with overhead mixers, stirring with homogenizers, shaking, microfluidization, refrigeration, and freezing.


Washing and Concentrating


In one embodiment, after the stabilization step is complete, the silver nanoplates can be washed to remove residual reactants or to exchange the solution with another solution. In various embodiments, the exchange of solution can be accomplished using dialysis, centrifugation, filtration, or tangential flow filtration. One embodiment of the invention is where the number of wash volumes exchanged within the sample is 1, 2, 3, 4, 5, between 1 and 5, between 5 to 10, between 10 to 20, or more than 20 wash volumes.


High optical density solutions of the nanoparticles can be fabricated using centrifugation, evaporation, filtration, dialysis or tangential flow filtration. One embodiment of this invention utilizes tangential flow filtration as the process of concentrating the silver nanoplate solution. The filter membrane utilized may be formed from a variety of materials. Specific filter membrane materials of interest include cellulose esters, polysulfone, and polyetheresulfone. The filter membrane utilized may have pores with a molecular weight cutoff of less than about 10 kD, between 10 kD to 500 kD, or more than about 500 kD (e.g., between 10 kD, to 100 kD, 10 kD to 500 kD, 20 kD to 500 kD, 20 kD to 250 kD), and/or pore sizes of less than about 0.05 between 0.05 μm and 0.5 or larger than about 0.5 μm (e.g., between 0.02 μm and 0.1 μm, 0.05 μm and 0.2 μm, 0.05 μm and 0.5 μm, 0.10 μm and 0.2 μm, 0.1 μm and 0.5 μm). Tangential flow filtration can also be utilized to change the solvent in which the silver nanoplates are dispersed. Specific solvents of interest include water and alcohols (e.g. t-butanol, ethanol, and isopropyl alcohol), as well as other polar or non-polar solvents. Additionally, tangential flow filtration can be utilized to remove residual chemicals.


This invention includes embodiments in which the silver nanoplate solution concentration is increased to produce a final solution with optical densities of greater than about 5 cm−1, greater than about 10 cm−1, greater than about 50 cm−1, greater than about 75 cm, greater than about 100 cm−1, greater than about 500 cm−1, or greater than about 1000 cm−1 (e.g., between 10 cm−1 to 100 cm−1, 30 cm−1 to 300 cm−1, 50 cm−1 to 500 cm−1, 100 cm−1 to 1000 cm−1, 300 cm−1 to 3000 cm−1, or 500 cm−1 to 5000 cm−1) One embodiment of the invention is where the silver nanoplate solution concentration is increased to above 106, 107, 108, 109, 1010, 1011, 1012, 1013 particles per milliliter.


Storage


One embodiment of the invention is where the concentrated particles are stored at temperatures below −10, 0, 4, 6, 10, or 20 degrees C.


One embodiment of the invention is where the particles are frozen and dried under vacuum. One embodiment is where the particles are freeze dried. One embodiment is where the particles are supercritically dried. Another embodiment is where an additional stabilant or other cryoprotectant is added to the solution before the particles are heat dried or freeze dried.


Composites


In one embodiment of the invention, high optical density solutions of silver nanoplates are associated with a substrate. Examples of substrates include fibers, cloth, mesh, bandages, socks, wraps, other articles of clothing, sponges, high porosity substrates, particles with diameters greater than 1 micron, beads, hair, skin, paper, absorbent polymers, foam, wood, cork, slides, roughened surfaces, biocompatible substrates, filters, or medical implants. In one embodiment, the high optical density solutions of silver nanoplates at a concentration of at least 1 mg/mL, 10 mg/mL, 100 mg/mL (e.g., 1 to 10, 3 to 30, 5 to 50, 10 to 20, 5 to 50, 3 to 50, 1 to 100 mg/mL, 10 to 100, 20 to 100, 30 to 100 mg/mL) are incubated with the substrate. In another embodiment, the high optical density solutions of silver nanoplates at a concentration of at least 1 mg/mL, 10 mg/mL, or 100 mg/mL (e.g., 1 to 10, 3 to 30, 5 to 50, 10 to 20, 5 to 50, 3 to 50, 1 to 100 mg/mL, 10 to 100, 20 to 100, 30 to 100 mg/mL) are incubated with the substrate. In another embodiment the silver nanoplates are prepared at an optical density of at least 10, 100, 300, 500, 1000, or 2000 cm−1 (e.g., between 10-100, 20-200, 30-300, 50-500, 100-1000, 200-1000, 300-1000, 500-1000, or 200-2000 cm−1) before incubating with the substrate. In another embodiment the substrate is chemically treated to increase the binding of the nanoplates to the substrate. For example, the substrate could be functionalized with a molecule that yielded a positively or negatively charged surface. In another embodiment, the pH of the incubating solution is selected in order to optimize binding. In another embodiment, the silver nanoplates cover at least 5%, 10%, 20%, 30%, 50% or 75% of the substrate (e.g., 5% to 10%, 10% to 100%, 10% to 50%, 50% to 100%, 30% to 100%, 30% to 70%, 40% to 80%, 50% to 90%, 60% to 100%, 70% to 100%, 80% to 100%, 90% to 100%, 0% to 5%, 1% to 10%, 2% to 20%, 5% to 30%, and/or 1% to 50% of the substrate). In another embodiment, other solvents or chemicals are added to the incubation solution. In another embodiment a biological linker (e.g. antibodies, peptides, DNA) is used to bind the high optical density silver nanoplates to the surface of the substrate. In one embodiment, the incubation is for less than 1 minute, 5 minutes, 20 minutes, 60 minutes, or 120 minutes (e.g., 0 to 1 minute, 1 minute to 120 minutes, 5 minutes to 120 minutes, 20 minutes to 120 minutes, 60 minutes to 120 minutes, 5 minutes to 60 minutes, 10 minutes to 60 minutes, 20 minutes to 60 minutes, 0 minutes to 10 minutes, 0 minutes to 20 minutes, or 0 minutes to 5 minutes).


In one embodiment, the substrate is separated from the incubating solution and dried. The substrate can be dried using air drying, heat drying, freeze drying, or supercritical drying. In another embodiment the dried substrate can be further processed by soaking the substrate in another material, painting the substrate with another material, or exposing the substrate to another material that is in the vapor phase.


Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as disclosing certain embodiments of the invention only, with a true scope and spirit of the invention being indicated by the following claims.


The subject matter described herein may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting. While embodiments are susceptible to various modifications, and alternative forms, specific examples thereof have been shown in the drawings and are herein described in detail. It should be understood, however, that the invention is not to be limited to the particular forms or methods disclosed, but to the contrary, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the various embodiments described and the appended claims. Any methods disclosed herein need not be performed in the order recited.


The methods disclosed herein include certain actions taken by a practitioner; however, they can also include any third-party instruction of those actions, either expressly or by implication. For example, actions such as “identifying a target region of skin tissue” include “instructing the identification of a target region of skin tissue.”


The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as “up to,” “at least,” “greater than,” “less than,” “between,” and the like includes the number recited. Numbers preceded by a term such as “about” or “approximately” or “substantially” include the recited numbers. For example, “about 3 mm” includes “3 mm.” The terms “approximately”, “about” and/or “substantially” as used herein represent an amount or characteristic close to the stated amount or characteristic that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount or characteristic.


EXAMPLES

Modern nanoparticle synthesis techniques have enabled the development of materials with unique optical properties for a wide range of applications including diagnostic, obscurant, and therapeutic applications. When as-fabricated nanoplates are concentrated using tangential flow filtration, the shape many of the plates shift to nanospheres, reducing the formulation efficacy, as evidenced by the increased peak height at 400 nm. By exchanging the surface capping agent of as-fabricated silver nanoplates with an agent that provides stability before, during, and/or after concentration, the silver nanoplates can be concentrated to increase the solution optical density without destabilizing the plates and degrading the beneficial optical properties.


The description of specific examples below are intended for purposes of illustration only and are not intended to limit the scope of the invention disclosed herein.


Example 1

15 L of silver nanoplates with a peak optical density of about 5 cm−1 were mixed with 3.5 g of polyvinylalcohol (PVA), and concentrated using tangential flow filtration using a 500 kD polysulfone tangential flow membrane with 3100 cm2 of surface area. The solution was concentrated for approximately 90 minutes, and the final solution volume was reduced from 15 L to 0.5 L. The increase of the silver nanoplate solution optical density was from 5 to about 150 cm−1. Thus, according to one embodiment, a method for increasing a silver nanoplate solution from 5 cm−1 to 150 cm−1 (e.g., an increase of roughly 30 times the optical density) comprises the steps of adding PVA to silver nanoplates, and concentrating the solution with tangential flow filtration.


Example 2

1.2 L of silver nanoplates with a peak optical density of about 4 cm−1 were mixed with 4 L of anhydrous ethanol and about 49 mL of ammonium hydroxide solution. 0.6 mL of a dilute aminopropyltriethoxysilane (APTES) was added to the solution. After 15 minutes of incubation, 6.5 mL of tetraethylorthosilicate (TEOS) solution was added. After 24 hours 1 L of the solution was concentrated using a 500 kD polysulfone tangential flow membrane with 1050 cm2 of surface area. The final solution volume was decreased to 150 mL, increasing the silver nanoparticle solution optical density to about 40 cm−1. Thus, according to one embodiment, a method for increasing a silver nanoplate solution from 4 cm−1 to 40 cm−1 (e.g., an increase of roughly 10 times the optical density) comprises the steps of adding anhydrous ethanol, ammonium hydroxide solution, aminopropyltriethoxysilane (APTES), and tetraethylorthosilicate (TEOS) to the silver nanoplates, and concentrating the solution with tangential flow filtration.


Example 3

A 40 mL solution of 40 O.D. solution of concentrated silver nanoplates was spun at 3000 RCF for 30 minutes. This processed was used to concentrate the silver nanoplates to an optical density of 1000 O.D.


Example 4

A 5 mL solution of 1000 OD silver nanoplates was added to a 3″×3″ section of absorbant cloth (Absorber Synthetic Drying Chamois, Clean Tools). After addition, the substrate was allowed to air dry. Once dried, the silver nanoplates were bound to the surface of the absorbant cloth and were not released when the cloth was subsequently wet and water removed by applying pressure.


REFERENCES

Aherne, D. L., D. M.; Gara, M.; Kelly, J. M., 2008: Optical Properties and Growth Aspects of Silver Nanoprisms Produced by Highly Reproducible and Rapid Synthesis at Room Temperature. Advanced Materials, 18, 2005-2016.


Chen, S., and D. L. Carroll, 2003: Controlling 2-dimensional growth of silver nanoplates. Self-Assembled Nanostructured Materials Symposium (Mater. Res. Soc. Symposium Proceedings Vol. 775), 343-348|xiii+394.


Chen, S. H., and D. L. Carroll, 2002: Synthesis and characterization of truncated triangular silver nanoplates. Nano Letters, 2, 1003-1007.


Chen, S. H., and D. L. Carroll, 2004: Silver nanoplates: Size control in two dimensions and formation mechanisms. Journal of Physical Chemistry B, 108, 5500-5506.


Chen, S. H., Z. Y. Fan, and D. L. Carroll, 2002: Silver nanodisks: Synthesis, characterization, and self-assembly. Journal of Physical Chemistry B, 106, 10777-10781.


Hao, E., G. C. Schatz, and J. T. Hupp, 2004: Synthesis and optical properties of anisotropic metal nanoparticles. Journal of Fluorescence, 14, 331-341.


Hao, E. K., K. L.; Hupp, J. T.; Schatz, G. C., 2002: Synthesis of Silver Nanodisks using Polystyrene Mesospheres as Templates. J Am Chem Soc, 124, 15182-15183.


He, X. Z., X.; Chen, Y.; Feng, J., 2008: The evidence for synthesis of truncated silver nanoplates in the presence of CTAB. Materials Characterization, 59, 380-384.


Jin, R., Y. Cao, C. A. Mirkin, K. L. Kelly, G. C. Schatz, and J. G. Zheng, 2001: Photoinduced Conversion of Silver Nanospheres to Nanoprisms. Science, 294, 1901-1903.


Jin, R., Y. C. Cao, E. Hao, G. S. Metraux, G. C. Schatz, and C. A. Mirkin, 2003: Controlling anisotropic nanoparticle growth through plasmon excitation. Nature, 425, 487.


Le Guevel, X. W., F. Y.; Stranik, O.; Nooney, R.; Gubala, V.; McDonagh, C.; MacCraith, B. D., 2009: Synthesis, Stabilization, and Functionalization of Silver Nanoplates for Biosensor Applications. J Phys Chem C, 113, 16380-16386.


Metraux, G. S. M., C. A; 2005: Rapid Thermal Synthesis of Silver Nanoprisms with Chemically Tailorable Thickness. Advanced Materials, 17, 412-415.


Xiong, Y. J., A. R. Siekkinen, J. G. Wang, Y. D. Yin, M. J. Kim, and Y. N. Xia, 2007: Synthesis of silver nanoplates at high yields by slowing down the polyol reduction of silver nitrate with polyacrylamide. Journal of Materials Chemistry, 17, 2600-2602.


Xue, C. M., C. A., 2007: pH-Switchable Silver Nanoprism Growth Pathways. Angew Chem Int Ed, 46, 2036-2038.


Each of the references listed above is incorporated by reference in its entirety.

Claims
  • 1. A process for increasing an optical density of a solution of stable, silver nanoplates to preserve shape post-concentration, comprising: providing a solution comprising silver nanoplates having a plate shape, an extinction spectra, and a first peak optical density between 0.1-10 cm−1;adding a concentration stabilizing chemical agent to the solution of silver nanoplates;adding borate to the solution of silver nanoplates; andincreasing the concentration of silver nanoplates in the solution to generate a concentrated solution using tangential flow filtration, thereby increasing the optical density of the concentrated solution to a second peak optical density greater than 10 cm−1,wherein the silver nanoplates in the concentrated solution retain the plate shape and the extinction spectra at the second peak optical density greater than 10 cm−1.
  • 2. The process of claim 1, wherein the stabilizing agent comprises at least one of the group consisting of polyvinyl pyrollidone, polyvinyl alcohol, polyethylene glycol, and dextran.
  • 3. The process of claim 1, wherein the stabilizing agent comprises at least one of the group consisting of polysulphonates, ethylene oxides, phenols, and carbohydrates.
  • 4. The process of claim 1, wherein the concentration stabilizing chemical agent is a water soluble polymer.
  • 5. The process of claim 1, wherein the concentration stabilizing chemical agent is a metal or metalloid oxide.
  • 6. The process of claim 5, wherein the stabilizing chemical agent is a silicon dioxide shell.
  • 7. The process of claim 6, wherein the silicon dioxide shell ranges in thickness from 1 nm to 100 nm.
  • 8. The process of claim 5, wherein the stabilizing chemical agent is a titanium dioxide shell.
  • 9. The process of claim 1, wherein a combination of stabilizing agents are used.
  • 10. The process of claim 1, further comprising adding any of the group selected from an acid, a base, and a buffering agent to the solution.
  • 11. The process of claim 1, wherein the silver nanoplates have an aspect ratio of between 1.5 and 25.
  • 12. The process of claim 1, wherein the silver nanoplates have an edge length between 10 nm and 250 nm.
  • 13. The process of claim 1, further providing the solution of silver nanoplates with a seed mediated growth method.
  • 14. The process of claim 1, wherein the concentrated solution of silver nanoplates is washed with between 1 and 5 wash volumes after increasing the concentration using tangential flow filtration.
  • 15. The process of claim 1, where the solution of silver nanoplates is incubated with a substrate.
  • 16. A process for increasing an optical density of a solution of stable silver nanoplates to preserve shape post-concentration, comprising: providing a solution comprising silver nanoplates having a plate shape,wherein the solution has an extinction spectra and a first peak optical density between 0.1-10 cm−1;adding a polyvinyl containing polymer and borate to the solution; andincreasing the concentration of silver nanoplates in the solution to generate a concentrated solution, thereby increasing the optical density of the concentrated solution to a second peak optical density greater than 10 cm−1,wherein the silver nanoplates in the concentrated solution retain the plate shape and the extinction spectra at the second peak optical density greater than 10 cm−1.
  • 17. The process of claim 16, wherein silver nanoplates have an individual edge length between 10 nm and 250 nm and an aspect ratio of between 1.5 and 25, and wherein the polyvinyl containing polymer comprises any one or more of the group consisting of: a polyvinyl alcohol and polyvinyl pyrrolidone.
  • 18. The process of claim 16, further comprising adding any one or more of the group consisting of: an acid, a base, and a buffering agent to the solution.
  • 19. The process of claim 16, further comprising providing via seed mediated growth the silver nanoplates with an aspect ratio of between 1.5 and 25 and associating the solution with a substrate.
  • 20. The process of claim 16, further comprising associating the silver nanoplates with skin.
INCORPORATION BY REFERENCE TO ANY PRIORITY APPLICATIONS

This application claims the benefit of priority from U.S. Provisional Application 61/795,149, filed on Oct. 11, 2012, which is incorporated by reference in its entirety. Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 CFR 1.57. The invention described herein was created subject to a Joint Research Agreement between Sienna Labs, Inc. and nanoComposix, Inc.

US Referenced Citations (293)
Number Name Date Kind
4526698 Kuroda et al. Jul 1985 A
5226907 Tankovich Jul 1993 A
5409797 Hosoi et al. Apr 1995 A
5423337 Ahlert et al. Jun 1995 A
5423803 Tankovich et al. Jun 1995 A
5425728 Tankovich Jun 1995 A
5553630 Dupuis et al. Sep 1996 A
5593680 Bara et al. Jan 1997 A
5647866 Zaias et al. Jul 1997 A
5695747 Forestier et al. Dec 1997 A
5713845 Tankovich Feb 1998 A
5750120 Miguel-Colombel May 1998 A
5752949 Tankovich et al. May 1998 A
5756110 Allard et al. May 1998 A
5776440 Forestier et al. Jul 1998 A
5814311 Le Bras-Roulier et al. Sep 1998 A
5817089 Tankovich et al. Oct 1998 A
5830177 Li et al. Nov 1998 A
5858381 Le Bras et al. Jan 1999 A
5863522 Forestier et al. Jan 1999 A
5925035 Tankovich Jul 1999 A
5955091 Hansenne Sep 1999 A
5958389 Le Bras-Roulier et al. Sep 1999 A
5985300 Crotty et al. Nov 1999 A
6004567 Marchi-Lemann et al. Dec 1999 A
6036684 Tankovich et al. Mar 2000 A
6050990 Tankovich et al. Apr 2000 A
6060041 Candau et al. May 2000 A
6063074 Tankovich May 2000 A
6080127 Li et al. Jun 2000 A
6132392 Stone Oct 2000 A
6132745 Marchi-Lemann et al. Oct 2000 A
6147982 Sourour et al. Nov 2000 A
6152917 Tankovich Nov 2000 A
6168590 Neev Jan 2001 B1
6183728 Forestier et al. Feb 2001 B1
6183773 Anderson Feb 2001 B1
6235270 Ishii et al. May 2001 B1
6238650 Lapidot et al. May 2001 B1
6267771 Tankovich et al. Jul 2001 B1
6283956 McDaniel Sep 2001 B1
6287549 Sumian et al. Sep 2001 B1
6333026 Lemann Dec 2001 B1
6344050 Chen Feb 2002 B1
6344272 Oldenburg et al. Feb 2002 B1
6365145 Ben-Hur et al. Apr 2002 B1
6403653 Hobson et al. Jun 2002 B1
6410603 Hobson et al. Jun 2002 B1
6428811 West et al. Aug 2002 B1
6461595 Leo et al. Oct 2002 B1
6491929 Anderson Dec 2002 B1
6517820 Robert Feb 2003 B1
6521241 Minerath, III et al. Feb 2003 B1
6530944 West et al. Mar 2003 B2
6534044 Wada et al. Mar 2003 B1
6541017 Lemann et al. Apr 2003 B1
6589538 Lemann et al. Jul 2003 B1
6600951 Anderson Jul 2003 B1
6620407 Gers-Barlag et al. Sep 2003 B1
6645517 West et al. Nov 2003 B2
6660381 Halas et al. Dec 2003 B2
6663658 Kollias et al. Dec 2003 B1
6676655 McDaniel Jan 2004 B2
6685730 West et al. Feb 2004 B2
6685927 Sumian et al. Feb 2004 B2
6685986 Oldenburg et al. Feb 2004 B2
6692755 Gers-Barlag et al. Feb 2004 B2
6699724 West et al. Mar 2004 B1
6706032 Weaver et al. Mar 2004 B2
6720006 Hanke et al. Apr 2004 B2
6767547 Gers-Barlag et al. Jul 2004 B2
6793913 Tournilhac et al. Sep 2004 B2
6800122 Anderson et al. Oct 2004 B2
6803049 Gers-Barlag et al. Oct 2004 B2
6811770 Ferrari et al. Nov 2004 B2
6814760 Anderson et al. Nov 2004 B2
6821509 Soane et al. Nov 2004 B2
6838088 Gers-Barlag et al. Jan 2005 B2
6852252 Halas et al. Feb 2005 B2
6881249 Anderson et al. Apr 2005 B2
6897238 Anderson May 2005 B2
6942878 Ishii et al. Sep 2005 B2
6955639 Hainfeld et al. Oct 2005 B2
6989151 Gers-Barlag et al. Jan 2006 B2
7018396 Sierra et al. Mar 2006 B2
7037513 Traynor et al. May 2006 B1
7131446 Tang et al. Nov 2006 B2
7144627 Halas et al. Dec 2006 B2
7201765 McDaniel Apr 2007 B2
7270721 Hilfenhaus et al. Sep 2007 B2
7367934 Hainfeld et al. May 2008 B2
7371457 Oldenburg et al. May 2008 B2
7435524 Anderson et al. Oct 2008 B2
7462496 Malak Dec 2008 B2
7494503 McDaniel Feb 2009 B2
7530940 Hainfeld et al. May 2009 B2
7648595 Jin et al. Jan 2010 B2
7659301 Anderson Feb 2010 B2
7704754 Malak Apr 2010 B2
7758561 Eppstein Jul 2010 B2
7758888 Lapidot et al. Jul 2010 B2
7776130 Mirkin et al. Aug 2010 B2
7780955 Cassin Aug 2010 B2
7785623 Keller Aug 2010 B2
7790066 Wang et al. Sep 2010 B2
7829073 Martin et al. Nov 2010 B2
7959624 Riesinger Jun 2011 B2
8033977 Hainfeld et al. Oct 2011 B2
8057418 Korbling et al. Nov 2011 B2
8062701 McClure et al. Nov 2011 B2
8178202 Halas et al. May 2012 B2
8182786 O'Brien et al. May 2012 B2
8197471 Tersigni Jun 2012 B1
8268332 Manstein Sep 2012 B2
8268638 Stein et al. Sep 2012 B2
8377427 Giroud et al. Feb 2013 B2
8420062 Josso Apr 2013 B2
8518445 Alfano et al. Aug 2013 B2
8591924 Zheng Nov 2013 B2
8613913 Chang et al. Dec 2013 B2
8617580 Toledano et al. Dec 2013 B2
8652495 Porter et al. Feb 2014 B2
8802154 Harris et al. Aug 2014 B2
8821940 Harris et al. Sep 2014 B2
8821941 Harris et al. Sep 2014 B2
8834447 Chen et al. Sep 2014 B2
8834933 Harris et al. Sep 2014 B2
8871711 Cotsarelis et al. Oct 2014 B2
8895071 Harris et al. Nov 2014 B1
8906418 Harris et al. Dec 2014 B1
20010002275 Oldenburg et al. May 2001 A1
20020009488 Francis et al. Jan 2002 A1
20020034480 Grimm et al. Mar 2002 A1
20020041854 Hadasch et al. Apr 2002 A1
20020061363 Halas et al. May 2002 A1
20020103517 West et al. Aug 2002 A1
20020132045 Halas et al. Sep 2002 A1
20020187172 Reb et al. Dec 2002 A1
20020192298 Burrell et al. Dec 2002 A1
20030060811 McDaniel Mar 2003 A1
20030072728 Soane et al. Apr 2003 A1
20030095941 Anderson May 2003 A1
20030099718 Burrell et al. May 2003 A1
20030118657 West et al. Jun 2003 A1
20030156991 Halas et al. Aug 2003 A1
20030215638 Charnay et al. Nov 2003 A1
20040006328 Anderson Jan 2004 A1
20040151673 Josso Aug 2004 A1
20040166508 Pawlak et al. Aug 2004 A1
20040170579 Mobius Sep 2004 A1
20040197286 Robert et al. Oct 2004 A1
20040219179 McDaniel Nov 2004 A1
20040253138 Malak Dec 2004 A1
20040253757 Gourlaouen et al. Dec 2004 A1
20050031655 Karpov Feb 2005 A1
20050031658 Girier Dufournier et al. Feb 2005 A1
20050044642 Butcher Mar 2005 A1
20050048546 Penn et al. Mar 2005 A1
20050053629 Ueda et al. Mar 2005 A1
20050058672 Gupta Mar 2005 A1
20050058678 Ricard et al. Mar 2005 A1
20050059030 Bao et al. Mar 2005 A1
20050130324 West et al. Jun 2005 A1
20050169866 Hannich et al. Aug 2005 A1
20050175649 Disalvo et al. Aug 2005 A1
20050186235 Martin et al. Aug 2005 A1
20050187128 Martin et al. Aug 2005 A1
20050203495 Malak Sep 2005 A1
20050220741 Dumousseaux Oct 2005 A1
20050229334 Huang et al. Oct 2005 A1
20060078578 Sandewicz et al. Apr 2006 A1
20060083762 Brun et al. Apr 2006 A1
20060257336 Ferrari et al. Nov 2006 A1
20070032781 Henry et al. Feb 2007 A1
20070065387 Beck et al. Mar 2007 A1
20070092471 Cassier et al. Apr 2007 A1
20070104605 Hampden-Smith et al. May 2007 A1
20070125383 Ko Jun 2007 A1
20070154903 Marla et al. Jul 2007 A1
20070158611 Oldenburg Jul 2007 A1
20070160636 Kasai Jul 2007 A1
20070166248 L'Alloret et al. Jul 2007 A1
20070183992 Dumousseaux et al. Aug 2007 A1
20070196305 Wang et al. Aug 2007 A1
20070208400 Nadkarni et al. Sep 2007 A1
20070217996 Levy et al. Sep 2007 A1
20070231940 Gourlaouen et al. Oct 2007 A1
20080045865 Kislev Feb 2008 A1
20080050448 Wilson et al. Feb 2008 A1
20080204742 Halas et al. Aug 2008 A1
20080233060 Grune Sep 2008 A1
20080241262 Lee et al. Oct 2008 A1
20080305337 Berning et al. Dec 2008 A1
20090022765 Chung et al. Jan 2009 A1
20090022766 Geddes Jan 2009 A1
20090053268 DePablo et al. Feb 2009 A1
20090123509 Berkland et al. May 2009 A1
20090175915 Maitra et al. Jul 2009 A1
20090177122 Peterson Jul 2009 A1
20090217465 Cremer et al. Sep 2009 A1
20090226521 Smyth et al. Sep 2009 A1
20090246142 Bhatia et al. Oct 2009 A1
20090291107 Schehlmann et al. Nov 2009 A1
20090326614 El-Sayed et al. Dec 2009 A1
20100002282 Agrawal et al. Jan 2010 A1
20100016783 Bourke, Jr. Jan 2010 A1
20100040549 Halas et al. Feb 2010 A1
20100055138 Margulies Mar 2010 A1
20100056485 Park Mar 2010 A1
20100057068 Lee Mar 2010 A1
20100104652 Biris et al. Apr 2010 A1
20100119610 Schoen et al. May 2010 A1
20100143431 Landau et al. Jun 2010 A1
20100172994 Sigmund et al. Jul 2010 A1
20100174223 Sakamoto et al. Jul 2010 A1
20100204686 Yarolslavksy et al. Aug 2010 A1
20100224026 Brennan Fournet et al. Sep 2010 A1
20100233222 Girier Dufournier et al. Sep 2010 A1
20100254920 L'Alloret et al. Oct 2010 A1
20100260700 Dop Oct 2010 A1
20100266647 Dingley et al. Oct 2010 A1
20100266649 Maitra et al. Oct 2010 A1
20100272789 Satoh et al. Oct 2010 A1
20100284924 Zink et al. Nov 2010 A1
20100291166 Guyot-Ferreol et al. Nov 2010 A1
20100291224 Tong et al. Nov 2010 A1
20100298758 Christansen et al. Nov 2010 A1
20100303716 Jin et al. Dec 2010 A1
20100305495 Anderson et al. Dec 2010 A1
20100323996 Ute et al. Dec 2010 A1
20110021970 Vo-Dinh et al. Jan 2011 A1
20110034855 Esenaliev Feb 2011 A1
20110052672 Krishnan et al. Mar 2011 A1
20110091572 Davidson Apr 2011 A1
20110111002 Pop May 2011 A1
20110117202 Bourke, Jr. et al. May 2011 A1
20110144030 Ramis Castelltort et al. Jun 2011 A1
20110159291 Sun et al. Jun 2011 A1
20110168200 Bourdin et al. Jul 2011 A1
20110223255 Thiesen et al. Sep 2011 A1
20110229559 Prestidge et al. Sep 2011 A1
20110240556 Hoek et al. Oct 2011 A1
20110288234 Pandey Nov 2011 A1
20120021030 Matsufuji et al. Jan 2012 A1
20120059307 Harris et al. Mar 2012 A1
20120101007 Ahern et al. Apr 2012 A1
20120141380 Margel et al. Jun 2012 A1
20120289955 Marc Nov 2012 A1
20130017238 Porter et al. Jan 2013 A1
20130022655 Sachweh et al. Jan 2013 A1
20130023714 Johnston et al. Jan 2013 A1
20130183244 Hanes et al. Jul 2013 A1
20130195979 Tersigni Aug 2013 A1
20130216596 Viladot Petit et al. Aug 2013 A1
20130225901 Krishnan et al. Aug 2013 A1
20130251825 Berry Sep 2013 A1
20130315650 Cassin et al. Nov 2013 A1
20130315999 Paithankar et al. Nov 2013 A1
20130323305 Paithankar et al. Dec 2013 A1
20130338545 Azhari et al. Dec 2013 A1
20140005593 Harris et al. Jan 2014 A1
20140012162 Harris et al. Jan 2014 A1
20140012163 Harris et al. Jan 2014 A1
20140012183 Harris et al. Jan 2014 A1
20140030300 Maitra et al. Jan 2014 A1
20140105982 Oldenburg et al. Apr 2014 A1
20140120041 Prencipe et al. May 2014 A1
20140120167 Lapotko et al. May 2014 A1
20140120168 Oldenburg et al. May 2014 A1
20140194900 Sedic Jul 2014 A1
20140205546 Macoviak Jul 2014 A1
20140243934 Vo-Dinh et al. Aug 2014 A1
20140271889 Messersmith et al. Sep 2014 A1
20140303525 Sitharaman Oct 2014 A1
20140316387 Harris et al. Oct 2014 A1
20140316394 Quidant et al. Oct 2014 A1
20140371654 Harris et al. Dec 2014 A1
20140371655 Harris et al. Dec 2014 A1
20140371656 Harris et al. Dec 2014 A1
20140371658 Harris et al. Dec 2014 A1
20140371659 Harris et al. Dec 2014 A1
20140371661 Harris et al. Dec 2014 A1
20140371662 Harris et al. Dec 2014 A1
20140371663 Harris et al. Dec 2014 A1
20140371664 Harris et al. Dec 2014 A1
20150005691 Harris et al. Jan 2015 A1
20150045723 Paithankar et al. Feb 2015 A1
20150165180 Anderson et al. Jun 2015 A1
20150190341 Paithankar et al. Jul 2015 A1
20150196359 Paithankar et al. Jul 2015 A1
20150196452 Meyer et al. Jul 2015 A1
20150196639 Lando et al. Jul 2015 A1
20150225599 Oldenburg et al. Aug 2015 A1
Foreign Referenced Citations (96)
Number Date Country
3905167 Aug 1989 DE
4344141 Jul 1995 DE
10342258 Apr 2005 DE
10351611 Aug 2005 DE
102004002990 Aug 2005 DE
102005007482 Sep 2006 DE
102007020554 Oct 2008 DE
102008052187 Apr 2010 DE
409690 Sep 1993 EP
518772 Nov 1994 EP
518773 Feb 1995 EP
555460 May 1995 EP
614656 Oct 1996 EP
586484 Jan 1998 EP
0 601 130 Aug 1998 EP
0 712 322 Apr 1999 EP
0925807 Jun 1999 EP
0860123 Jan 2002 EP
966954 Feb 2002 EP
1112325 May 2003 EP
1185242 Aug 2005 EP
1201219 Dec 2005 EP
1325730 Oct 2006 EP
1506764 Apr 2007 EP
1506763 Jul 2007 EP
1506765 Jul 2007 EP
1506766 Jul 2007 EP
1529513 Mar 2008 EP
1317245 May 2008 EP
1677843 Aug 2008 EP
1744789 Aug 2008 EP
1768749 Oct 2008 EP
1267801 Dec 2008 EP
1559393 May 2009 EP
1559394 Mar 2010 EP
1208005 Apr 2010 EP
1861465 Oct 2010 EP
1502574 Nov 2010 EP
1167462 Dec 2010 EP
2231283 Sep 2012 EP
988853 Oct 2012 EP
1263447 Jun 2013 EP
2396010 Aug 2013 EP
2416752 Sep 2013 EP
1267747 Jan 2014 EP
1959914 May 2014 EP
WO9106894 May 1991 WO
WO 9533518 Dec 1995 WO
WO 9620698 Jul 1996 WO
WO 9641579 Dec 1996 WO
WO 9700098 Jan 1997 WO
WO 9946351 Sep 1999 WO
WO 0002590 Jan 2000 WO
WO 0040266 Jul 2000 WO
WO 0105586 Jan 2001 WO
WO 0106257 Jan 2001 WO
WO 0158458 Aug 2001 WO
WO 02085385 Oct 2002 WO
WO 03026481 Apr 2003 WO
WO 2004058352 Jul 2004 WO
WO 2004086044 Oct 2004 WO
WO2005077329 Aug 2005 WO
WO 2005092286 Oct 2005 WO
WO 2006122222 Nov 2006 WO
WO2008079758 Jul 2008 WO
WO2008079760 Jul 2008 WO
WO 2008106966 Sep 2008 WO
WO 2009117124 Sep 2009 WO
WO 2010073260 Jul 2010 WO
WO2010109545 Sep 2010 WO
WO 2010116345 Oct 2010 WO
WO 2010116346 Oct 2010 WO
WO2010137580 Dec 2010 WO
WO2011013101 Feb 2011 WO
WO 2011031871 Mar 2011 WO
WO 2011116963 Sep 2011 WO
WO 2012027728 Mar 2012 WO
WO2012035029 Mar 2012 WO
WO2013106998 Jul 2013 WO
WO2013106999 Jul 2013 WO
WO2013107000 Jul 2013 WO
WO2013107001 Jul 2013 WO
WO2013107002 Jul 2013 WO
WO2013107349 Jul 2013 WO
WO2013107350 Jul 2013 WO
WO2013107351 Jul 2013 WO
WO2013107352 Jul 2013 WO
WO2013107353 Jul 2013 WO
WO2013107354 Jul 2013 WO
WO 2013158278 Oct 2013 WO
WO2013160362 Oct 2013 WO
WO2013169955 Nov 2013 WO
WO2014026142 Feb 2014 WO
WO2014052973 Apr 2014 WO
WO2014145784 Sep 2014 WO
WO2014145784 Sep 2014 WO
Non-Patent Literature Citations (72)
Entry
Dierickx, et al. “Photodynamic Therapy for Nevus Sebaceus With Topical d-Aminolevulinic Acid”, Arch Dermatol, vol. 135, Jun. 1993, pp. 637-640.
Divaris, et al. “Phototoxic Damage to Sebaceous Glands and Hair Follicles of Mice After Systemic Administration of 5-Aminolevulinic Acid Correlates with Localized Protoporphyrin IX Florescence”, American Journal of Pathology, vol. 136, No. 4, Apr. 1990, pp. 891-897.
Hongcharu, et al. “Topical ALA-Photodynamic Therapy for the Treatment of Acne Vulgaris”, Journal of Invest. Dermatology, vol. 115, No. 2, Aug. 2000, pp. 1-10.
Kjeldstad, et al. “Changes in Polyphosphate Composition and Localization in Propionibacterium Acnes After Near-Ultraviolet Irradiation”, Canadian Journal of Microbiology, vol. 37, No. 7, Jul. 1991, 562-567 (Abstract, 1 Page).
Koenig, et al. “Photodynamic-Induced Inactivation of Propionibacterium Acnes”, SPIE Proceedings, SPIE-Int. Soc. Opt. Eng., 106-110, vol. 3247, Jan. 1998 (Abstract, 3 Pages).
Konig, et al. “Photodynamic Activity of Methylene Blue”, Aktuelle Dermatol, vol. 19, 1993, pp. 195-198.
Konig, et al. “Photodynamically Induced Inactivation of Propionibacterium Acnes Using the Photosensitizer Methylene Blue and Red Light”, Dermatologische Monatsschrift (Dematol Monatsschr), vol. 178, Apr. 1992, pp. 297-300.
Lloyd, et al. “Selective Photothermolysis of the Sebaceous Glands for Acne Treatment”, Lasers in Surgery and Medicine, vol. 31, 2002, pp. 115-120.
Mills, et al. “Ultraviolet Phototherapy and Photochemotherapy of Acne Vulgaris”, Arch Dematol, vol. 114, No. 2, Feb. 1978 (Abstract, 2 pages).
Mutzhas, et al. “A New Apparatus with High Radiation Energy Between 320-460 nm: Physical Description and Dermatological Applications”, The Journal of Investigative Dermatology, vol. 76, No. 1, Jan. 1981, pp. 42-47.
Pento, et al. “Delta-Aminolevulinic Acid”, Drugs of the Future, vol. 22, No. 1, 1997, pp. 11-17.
Phillips, et al. “Medical Progress: Recent Advances in Dermatology”, New England Journal of Medicine, vol. 326, No. 3, Jan. 1992, pp. 1-9 (167-176).
Wainwright, Mark “Non-Porphyrin Photosensitizers in Biomedicine”, Chemical Society Reviews, 1996, pp. 351-359.
Amirthalingam et al. “Use of Silica-Gold Core Shell Structure Nanoparticles for Targeted Drug Delivery System” J. Nanomedic Nanotechnol 2:119, (2011) vol. 2, Issue 6.
Bukasov et al. “Nano Letters—Highly tunable infrared extinction properties of gold nanocrescents.” American Chemical Society, vol. 7, No. 5 May 2007, published on web Apr. 14, 2007.
Ghaffarpour, Azizjalali M. et al., “CO2 Laser therapy versus cryotherapy in treatment of genital warts; a Randomized Controlled Trial (RCT)”, Iranian Journal of Microbiology, vol. 4, No. 4, Dec. 2012, 187-190.
Kulkarni et al., “Effect of Experimental Temperature on the Permeation of Model Diffusants Across Porcine Buccal Mucosa” AAPS PharmSciTech. Jun. 2011; 12(2)579.
Lazare, M. What are Cold Sores (Herpetic Lesions)?, http://www.drmarclazare.com/laser-treatments-for-cold-soresherpetic-lesions/, dated Jul. 8, 2014.
Lewicka et al. “Nanorings and nanocrescents formed via shaped nanosphere lithography: a route toward large areas of infrared metamaterials.” IOP Publishing, Nanotechnology 24: Feb. 28, 2013.
Maltzahn, Geoffrey von, et al., “Computationally Guided Photothermal Tumor Therapy Using Long-Circulating Gold Nanorod Antennas” Cancer Res 2009; 69: (9) Published online Apr. 14, 2009 as 10.11158/008-5472.CAN-08-4242.
Rallis, Tena M., “Low-Intensity Laser Therapy for Recurrent Herpes Labialis” The Journal of Investigative Dermatology, vol. 115, No. 1 Jul. 2000.
Prosecution history (excluding references of record) of U.S. Appl. No. 13/789,575, namely an Amendment and a Suggestion for Declaration of Interference (with Appendices) over US Publication 2014/0005593 with U.S. Appl. No. 14/020,481, now U.S. Pat. No. 8,821,941. The Amendment and Suggestion for Declaration of Interference (with Appendices) and related documentation is dated Jul. 28, 2015 (submission date to USPTO) (Part 1 of 5).
Prosecution history (excluding references of record) of U.S. Appl. No. 13/789,575, namely Exhibits from a Suggestion for Declaration of Interference over US Publication 2014/0005593 with U.S. Appl. No. 14/020,481, now U.S. Pat. No. 8,821,941. The Exhibits from a Suggestion for Declaration of Interference and related documentation is dated Jul. 28, 2015 (submission date to USPTO) (Part 2 of 5).
Prosecution history (excluding references of record) of U.S. Appl. No. 13/789,575, namely Exhibits from a Suggestion for Declaration of Interference over US Publication 2014/0005593 with U.S. Appl. No. 14/020,481, now U.S. Pat. No. 8,821,941. The Exhibits from a Suggestion for Declaration of Interference and related documentation is dated Jul. 28, 2015 (submission date to USPTO) (Part 3 of 5).
Prosecution history (excluding references of record) of U.S. Appl. No. 13/789,575, namely Exhibits from a Suggestion for Declaration of Interference over US Publication 2014/0005593 with U.S. Appl. No. 14/020,481, now U.S. Pat. No. 8,821,941. The Exhibits from a Suggestion for Declaration of Interference and related documentation is dated Jul. 28, 2015 (submission date to USPTO) (Part 4 of 5).
Prosecution history (excluding references of record) of U.S. Appl. No. 13/789,575, namely Exhibits from a Suggestion for Declaration of Interference over US Publication 2014/0005593 with U.S. Appl. No. 14/020,481, now U.S. Pat. No. 8,821,941. The Exhibits from a Suggestion for Declaration of Interference and related documentation is dated Jul. 28, 2015 (submission date to USPTO) (Part 5 of 5).
Prosecution history (excluding references of record) of U.S. Appl. No. 13/789,575, namely an amendment in view of a Suggestion for Declaration of Interference over US Publication 2014/0005593 with U.S. Appl. No. 14/020,481, now U.S. Pat. No. 8,821,941. The amendment and related documentation is dated Aug. 19, 2015 (submission date to USPTO).
Prosecution history (excluding references of record) of U.S. Appl. No. 13/789,575, namely an Advisory Action further to a Suggestion for Declaration of Interference over US Publication 2014/0005593 with U.S. Appl. No. 14/020,481, now U.S. Pat. No. 8,821,941. The Advisory Action and related documentation is dated Aug. 21, 2015 (mailing date from USPTO).
Aherne, et al. “Optical Properties and Growth Aspects of Silver Nanoprisms Produced by Highly Reproducible and Rapid Synthesis at Room Temperature.” Advanced Materials, Adv. Funct. Mater. Jul. 9, 2008, v18, 2005-2016.
Ammad et al. “An assessment of the efficacy of blue light phototherapy in the treatment of acne vulgaris.” J. Cosmet Dermatol, 2008, 7: 180-188.
Charles et al. “Versatile Solution Phase Triangular Silver Nanoplats for Highly Sensitive Plasmon Resonance Sensing” American Chemical Society NANO, v4, No. 1 p. 55-64, Dec. 23, 2009.
Chen et al. “Controlling 2-dimensional growth of silver nanoplates.” Self-Assembled Nanostructured Materials Symposium. Mat. Res. Soc. Symp. Proc. vol. 775, 343-348|xiii+394. (2003).
Chen et al. “Silver nanodisks: Synthesis, characterization, and self-assembly.” J. Phys. Chem. B, vol. 106, No. 42, 2002 10777-10781. (Published Sep. 21, 2002).
Chen, et al. “Silver nanoplates: Size control in two dimensions and formation mechanisms.” J. Phys. Chem. B 2004, 108, 5500-5506 Journal of Physical Chemistry B, 108, 5500-5506. (Published Apr. 14, 2004).
Chen, et al. “Synthesis and characterization of truncated triangular silver nanoplates.” Nano Letters, 2002, 2 (9), 1003-1007. (Published Jul. 26, 2002).
Choudhary and Elsaie, M.L. “Photodynamic therapy in dermatology: a review.” Lasers Med Sci., 2009, 24:971-980.
Donnelly et al. “Photosensitiser delivery for photodynamic therapy. Part 1: Topical carrier platforms.” Expert Opin Drug Deliv. 2008, 5:757-766.
Gollnick et al. “Can we define acne as a chronic disease? If so, how and when?” Am J Clin Dermatol, 2008, 9:279-284.
Grachtchouk et al. “Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations.” J Clin Invest, 2011, 121: 1768-1781.
Grams et al. “Permeant lipophilicity and vehicle composition influence accumulation of dyes in hair follicles of human skin,” Eur J Pharm Sci, 2003, 18:329-336.
Hao E. K., et al. “Synthesis of Silver Nanodisks using Polystyrene Mesospheres as Templates.” J Am Chem Soc, 124, 15182-15183. (Published Nov. 22, 2002).
Hao E., et al. “Synthesis and optical properties of anisotropic metal nanoparticles.” Journal of Fluorescence, vol. 14, No. 4, Jul. 2004, 331-341. (Published Jul. 2004).
He et al. “Surface Plasmon Resonances of Silver Triange Nanoplates: Graphic Assignments of Resonance Modes and Linear Fittings of Resonance Peaks” J. Phys. Chem. B 2005, 109, 17503-17511 (Published Aug. 20, 2005).
He, et al. “The evidence for synthesis of truncated silver nanoplates in the presence of CTAB.” Materials Characterization, 59, 380-384. (Publshed 2008).
Hongcharu et al. “Topical ALA-photodynamic therapy for the treatment of acne vulgaris.” J Invest Dermatol, 2000, 115:183-192.
Huang et al. Microemulsification of triglyceride sebum and the role of interfacial structure on bicontinuous phase behavior.: Langmuir, 2004, 20:3559-3563.
Jiang et al. “A self-seeding coreduction method for shape control of silver nanoplates” Nanotechnology 17 (2006) 4929-4935 (Published Sep. 11, 2006).
Jin et al. “Photoinduced Conversion of Silver Nanospheres to Nanoprisms.” Science, v 294, 1901-1903. (Published Nov. 30, 2001).
Jin, et al. “Controlling anisotropic nanoparticle growth through plasmon excitation.” Nature, v. 425, 487-490 (Published Oct. 2, 2003).
Knorr et al. “Follicular transport route-research progress and future perspectives.” Eur J Pharm Biopharm, 2009, 71:173-180.
Lademann et al. “Nanoparticles—an efficient carrier for drug delivery into the hair follicles.” Eur J Pharm Biopharm, 2007, 66:159-164.
Le Guevel, et al. “Synthesis, Stabilization, and Functionalization of Silver Nanoplates for Biosensor Applications.” J Phys Chem C, 113, 16380-16386. (Published Aug. 21, 2009).
Mallon et al. “The quality of life in acne: a comparison with general medical conditions using generic questionnaires.” Br J Dermatol, 1999, 140:672-676.
Meidan, V.M. “Methods for quantifying intrafollicular drug delivery: a critical appraisal.” Expert Opin Drug Deliv, 2010, 7:1095-1108.
Metraux, G. S. M. et al “Rapid Thermal Synthesis of Silver Nanoprisms with Chemically Tailorable Thickness.” Advanced Materials, 2005, 17, No. 4, 412-415. (Published Feb. 23, 2005).
Mitragotri et al. “Synergistic effect of low-frequency ultrasound and sodium lauryl sulfate on transdermal transport.” J Pharm Sci, 2000, 89:892-900.
Mortensen et al. “In vivo skin penetration of quantum dot nanoparticles in the murine model: the effect of UVR.” Nano Lett, 2008, 8:2779-2787.
Nanni, C.A. and Alster, T.S. (1997). “Optimizing treatment parameters for hair removal using a topical carbon-based solution and 1064-nm Q-switched neodymium: YAG laser energy.” Arch Dermatol, 1997, 133:1546-1549.
Polat et al. “Ultrasound-mediated transdermal drug delivery: Mechanisms, scope, and emerging trends.” J Control Release, 2011, 152:330-348.
Rogers et al. “Hair removal using topical suspension-assisted Q-switched Nd: YAG and long-pulsed alexandrite lasers: A comparative study.” Dermatol Surg, 1999, 25:844-844; discussion 848-850.
Sakamoto et al. “Photodynamic therapy for acne vulgaris: A critical review from basics to clinical practice: Part 1, Acne Vulgaris: When and why consider photodynamic therapy?” Journal of the American Academy of Dermatology, 2010, 63:183-193.
Sakamoto et al. “Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: Part II. Understanding parameters for acne treatment with photodynamic therapy.” Journal of the Academy of Dermatology, 2010, 63:195-211.
Schultz, et al. “The Chemorheology of Poly(vinyl alcohol)-Borate Gels.” Macromolecules, vol. 2, No. 3, 281-285. (Published May-Jun. 1969).
Sellheyer, K. “Basal cell carcinoma: cell of origin, cancer stem cell hypothesis and stem cell markers.” Br J Dermatol, 2011, 164:696-711.
Sellheyer, K. (2007). “Mechanisms of laser hair removal: could persistent photoepilation induce vitiligo or defects in wound repair?” Dermatol Surg, 2007, 33:055-1065.
Shershen et al. “Temperature-Sensitive Polymer—Nanoshell Composites for Photothermally Modulated Drug Delivery” Journal of Biomedical Materials Research; vol. 51, Issue 3, pp. 293-298 (Jun. 28, 2000).
West et al. “Applications of Nanotechnology to Biotechnology” Current Opinion in Biotechnology 2000, 11:215-217; Published Apr. 1, 2000.
Wong, S.Y., and Reiter, J.F. “Wounding mobilizes hair follicle stem cells to form tumors.” Proc Natl Acad Sci USA, 2011, 108:4093-4098.
Xiong, et al. “Synthesis of silver nanoplates at high yields by slowing down the polyol reduction of silver nitrate with polyacrylamide.” Journal of Materials Chemistry, 17, 2600-2602. (Published May 17, 2007).
Xue, et al. “pH-Switchable Silver Nanoprism Growth Pathways.” Angew. Chem. Int. Ed., 46, 2036-2038. (Published Feb. 13, 2007).
Zhao, W., and Karp, J.M. “Tumour targeting: Nanoantennas heat up.” Nat Mater, 2009, 8:453-454.
Prosecution history (excluding references of record) of U.S. Appl. No. 13/789,575, including a 37 CFR 1.131 declaration over US Publication 2014/0005593 with U.S. Appl. No. 14/020,481, now U.S. Pat. No. 8,821,941. The 131 declaration is dated Dec. 31, 2014 (submission date to USPTO).
Related Publications (1)
Number Date Country
20140105982 A1 Apr 2014 US
Provisional Applications (1)
Number Date Country
61795149 Oct 2012 US